Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 3:8:40.
doi: 10.3389/fendo.2017.00040. eCollection 2017.

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters

Victor J Geraedts  1 , Cornelie D Andela  2 , Günter K Stalla  3 , Alberto M Pereira  2 , Wouter R van Furth  4 , Caroline Sievers  3 , Nienke R Biermasz  2
Affiliations
Review

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters

Victor J Geraedts et al. Front Endocrinol (Lausanne). .

Abstract

Background: Quality of life (QoL) in patients with acromegaly is reduced irrespective of disease state. The contributions of multifactorial determinants of QoL in several disease stages are presently not well known.

Objective: To systematically review predictors of QoL in acromegalic patients.

Methods: Main databases were systematically searched using predefined search terms for potentially relevant articles up to January 2017. Inclusion criteria included separate acromegaly cohort, non-hereditary acromegaly, QoL as study parameter with clearly described method of measurement and quantitative results, N ≥ 10 patients, article in English and adult patients only. Data extraction was performed by two independent reviewers; studies were included using the PRISMA flow diagram.

Results: We identified 1,162 studies; 51 studies met the inclusion criteria: 31 cross-sectional observational studies [mean AcroQoL score 62.7 (range 46.6-87.0, n = 1,597)], 9 had a longitudinal component [mean baseline AcroQoL score 61.4 (range 54.3-69.0, n = 386)], and 15 were intervention studies [mean baseline AcroQoL score 58.6 (range 52.2-75.3, n = 521)]. Disease-activity reflected by biochemical control measures yielded mixed, and therefore inconclusive results with respect to their effect on QoL. Addition of pegvisomant to somatostatin analogs and start of lanreotide autogel resulted in improvement in QoL. Data from intervention studies on other treatment modalities were too limited to draw conclusions on the effects of these modalities on QoL. Interestingly, higher BMI and greater degree of depression showed consistently negative associations with QoL. Hypopituitarism was not significantly correlated with QoL in acromegaly.

Conclusion: At present, there is insufficient published data to support that biochemical control, or treatment of acromegaly in general, is associated with improved QoL. Studies with somatostatin receptor ligand treatment, i.e., particularly lanreotide autogel and pegvisomant have shown improved QoL, but consensus on the correlation with biochemical control is missing. Longitudinal studies investigating predictors in treatment-naive patients and their follow-up after therapeutic interventions are lacking but are urgently needed. Other factors, i.e., depression and obesity were identified from cross-sectional cohort studies as consistent factors associated with poor QoL. Perhaps treatment strategies of acromegaly patients should not only focus on normalizing biochemical markers but emphasize improvement of QoL by alternative interventions such as psychosocial or weight lowering interventions.

Keywords: acromegaly; biochemical control; depression; quality of life; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interpretation of the setting of the studied predictors.
Figure 2
Figure 2
Prisma flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med (1995) 41(10):1403–9. - PubMed
    1. Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers; (1996). p. 11–23.
    1. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De ML, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol (2012) 167(2):189–98.10.1530/EJE-12-0084 - DOI - PubMed
    1. Mercado M, Gonzalez B, Vargas G, Ramirez C, Espinosa de Los Monteros AL, Sosa E, et al. Successful mortality reduction and control of co-morbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab (2014) 99(12):4438–46.10.1210/jc.2014-2670 - DOI - PubMed
    1. Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol (2013) 168(1):39–47.10.1530/EJE-12-0602 - DOI - PubMed

LinkOut - more resources